RxDoctor Payments Data

Christopher Colglazier, MD

Rheumatology · Crestview Hills, KYNPI 1679555486

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $17,842 of the $22,392 with a category attached, or 79.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $7,160 and has fallen 68.0% since, to $2,289 in 2025.

$22,392in general payments, 2019–2025

Across 1,014 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Lilly USA, LLC$4K
  • Amgen$3K
  • Johnson & Johnson$3K
  • UCB, Inc.$2K
  • Novartis$1K
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$4,17519%
  • Food & beverage$17,84280%
  • Education$3762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,392 in reported general payments places this provider in the 85th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,415,360
Medicare patients
350
Services billed
144,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast38$183,290
Humira PenAdalimumab24$154,281
SimponiGolimumab15$131,528
Orencia ClickjectAbatacept23$112,022
RinvoqUpadacitinib12$103,523
EnbrelEtanercept11$79,835
Humira(Cf) PenAdalimumab11$74,930
Xeljanz XrTofacitinib Citrate11$73,730
BenlystaBelimumab12$58,144
Cimzia (2 Pack)Certolizumab Pegol12$47,201
Celecoxib316$15,694
Hydroxychloroquine Sulfate286$9,198
Pregabalin95$5,069
Cevimeline Hcl14$3,727
Febuxostat20$3,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$3,175$263,12449 claims
Johnson & JohnsonSimponi$3,029$131,52815 claims
AbbVieRinvoq$4,539$103,52312 claims
GSKBenlysta$338$58,14412 claims
UCB, Inc.Cimzia (2 Pack)$1,973$47,20112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 rheumatology providers in Kentucky.

Other rheumatology in Crestview Hills

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →